Denmark’s Novo Nordisk Pharmatech has partnered with the Performance Materials business unit of DKSH, a major ingredients and specialty chemicals distributor specializing in Asia, to distribute the Danish company’s pharmaceutical grade compounds (quats) to its customer base in Australia, New Zealand, Japan, Indonesia, South Korea, Thailand, Malaysia, Philippines, China, Taiwan and Singapore.

Novo Nordisk said it chose DKSH for its “proven experience” in providing market expansion services along the entire value chain and for its solid logistics infrastructure,” in particular the omni-channel approach that presents a one-stop regional solution for its clients.

DSKH’s ”tailored valued-added services and a deep capillary distribution network will enable the distribution of Novo Nordisk's products in the eleven markets across Asia Pacific,” the company added.

Tanja Schaffer, vice president, Global Pharmaceutical Industry, at DKSH, said Novo Nordisk Pharmatech’s pharmaceutical grade quats “are a perfect fit” for its portfolio that it looks forward to providing to its large customer base in the region.

Steve Profit, Global Sales & Marketing Director at the Novo Nordisk unit, said his company’s FeF(r) GMP quats products “fit perfectly with DKSH's wide range of excipients, enabling the customers to take advantage of these synergies.”

Novo Nordisk Pharmatech manufactures its pharmaceutical quats in accordance with the cGMP Guide ICH Q7 for Active Pharmaceutical Ingredients (APIs). The quats, Benzalkonium Chloride (BKC), Cetrimonium Bromide (CTAB), Cetrimide and Strong Cetrimide, act either as preservatives or active ingredients in a diverse range of applications, including ophthalmic, nasal, oral, dental or topical treatments and medical devices, such as wound care.